Patents Examined by George C. Elliott
  • Patent number: 6140124
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: October 31, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Pamela S. Nero, Robert McKay
  • Patent number: 6136965
    Abstract: The invention provides novel deoxynucleic alkyl thiourea (dNXt) oligonucleotide compounds for use in antisense or antigene therapy.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: October 24, 2000
    Assignee: The Regents of the University of California
    Inventors: Thomas C. Bruice, Dev P. Arya
  • Patent number: 6136547
    Abstract: The invention concerns the human gene encoding GLUTX, a glucose transporter. GLUTX nucleic acid and polypeptides, as well as molecules which increase or decrease expression or activity of GLUTX, are useful in the diagnosis and treatment of disorders associated with aberrant hexose transport.
    Type: Grant
    Filed: April 26, 1999
    Date of Patent: October 24, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Louis A. Tartaglia, Xun Weng
  • Patent number: 6136603
    Abstract: Compositions and methods are provided for antisense modulation of interleukin-5 signal transduction. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding interleukin-5 and interleukin-5 receptor.alpha. are preferred. Methods of using these compounds for modulation of interleukin-5 signal transduction and for treatment of diseases associated with interleukin-5 signal transduction are also provided.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: October 24, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, James G. Karras, Robert McKay
  • Patent number: 6136604
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of methionine aminopeptidase 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding methionine aminopeptidase 2. Methods of using these compounds for modulation of methionine aminopeptidase 2 expression and for treatment of diseases associated with expression of methionine aminopeptidase 2 are provided.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: October 24, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Jacqueline Wyatt
  • Patent number: 6133031
    Abstract: Compounds, compositions and methods are provided for inhibiting FAK mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding FAK. Methods of using these antisense compounds for inhibition of FAK expression and for treatment of diseases, particularly cancers, associated with overexpression or constitutive activation of FAK are provided.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: October 17, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, William A. Gaarde
  • Patent number: 6133038
    Abstract: The invention provides platinum-based probe compounds having the structure: ##STR1## wherein: Pt is a platinum atom, PROBE is a probe biomolecule for associating to a target biomolecule, M is a detectable marker moiety, and X and Y are stabilizing substituents. Also provided are platinum-based labeling compounds having the structure: ##STR2## wherein: Pt is a platinum atom, M is a detectable marker moiety, A is a displaceable leaving group, and X and Y are stabilizing substituents. The invention further provides platinum-based linker compounds having the structure: ##STR3## wherein: Pt is a platinum atom, A and B are the same or different reactive moieties, and X and Y are stabilizing substituents. Other Pt.sup.II and Pt.sup.IV compounds are also provided. Moreover, the invention provides methods for the preparation and use of these compounds, as well as diagnostic kits which contain the compounds.
    Type: Grant
    Filed: August 10, 1998
    Date of Patent: October 17, 2000
    Assignee: Kreatech Diagnostics
    Inventors: Hendrik J. Houthoff, Jan Reedijk, Tinka Jelsma, Remco Maria Van Es, Franciscus Michiel van den Berg, Edwin Leo Mario Lempers, Marieke Johanna Bloemink
  • Patent number: 6132997
    Abstract: Methods for linearly amplifying mRNA to produce antisense RNA are provided. In the subject methods, mRNA is converted to double-stranded cDNA using a promoter-primer having a poly-dT primer site linked to a promoter sequence so that the resulting double-stranded cDNA is recognized by an RNA polymerase. The resultant double-stranded cDNA is then transcribed into antisense RNA in the presence of a reverse transcriptase that is rendered incapable of RNA-dependent DNA polymerase activity during this transcription step. The subject methods find use a variety of different applications in which the preparation of linearly amplified amounts of antisense RNA is desired. Also provided are kits for practicing the subject methods.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: October 17, 2000
    Assignee: Agilent Technologies
    Inventor: Karen W. Shannon
  • Patent number: 6133032
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3 kinase p110 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3 kinase p110 beta. Methods of using these compounds for modulation of PI3 kinase p110 beta expression and for treatment of diseases associated with expression of PI3 kinase p110 beta are provided.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: October 17, 2000
    Assignee: Isis Pharmaceutical Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Patent number: 6132966
    Abstract: An enzymatic RNA molecule which specifically cleaves RNA of a hepatitis C virus.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: October 17, 2000
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: Kenneth G. Draper
  • Patent number: 6133437
    Abstract: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: October 17, 2000
    Assignee: Apoptogen, Inc.
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Peter Liston, Stephen Baird, Benjamin K. Tsang, Christine Pratt
  • Patent number: 6132965
    Abstract: A method for diagnosing hyperhomocysteinemia by molecular genetic means is disclosed.
    Type: Grant
    Filed: January 30, 1998
    Date of Patent: October 17, 2000
    Assignee: Hamilton Civic Hospitals Research Development Inc.
    Inventors: Richard C. Austin, Jack Hirsh, Jeffrey I. Weitz
  • Patent number: 6130092
    Abstract: A ribozyme library which comprises a collection of ribozyme genes encoding a hammerhead structure and flanking sequences of random nucleotides cloned at least once into an expression cassette for ribozyme expression.
    Type: Grant
    Filed: July 3, 1997
    Date of Patent: October 10, 2000
    Assignee: Max-Planck Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Andre Lieber, Michael Strauss, deceased
  • Patent number: 6130038
    Abstract: The present invention concerns oligonucleotides containing one or more modified nucleotides which increase the binding affinity of the oligonucleotides to target nucleic acids having a complementary nucleotide base sequence. These modified oligonucleotides hybridize to the target sequence at a faster rate than unmodified oligonucleotides having an identical nucleotide base sequence. Such modified oligonucleotides include oligonucleotides containing at least one 2'-O-methylribofuranosyl moiety joined to a nitrogenous base. Oligonucleotides can be modified in accordance with the present invention to preferentially bind RNA targets. The present invention also concerns methods of using these modified oligonucleotides and kits containing the same.
    Type: Grant
    Filed: July 15, 1997
    Date of Patent: October 10, 2000
    Assignee: Gen-Probe Incorporated
    Inventors: Michael M. Becker, Mehrdad Majlessi, Steven T. Brentano
  • Patent number: 6130088
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Telomeric Repeat Binding Factor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Telomeric Repeat Binding Factor 1. Methods of using these compounds for modulation of Telomeric Repeat Binding Factor 1 expression and for treatment of diseases associated with expression of Telomeric Repeat Binding Factor 1 are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: October 10, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Patent number: 6127114
    Abstract: Compounds having highly specific endoribonuclease activity are described. The compounds of this invention, also known as ribozymes, comprise ribonucleotides having two hybridizing regions with predetermined sequences capable of hybridizing with a plant, animal or viral target RNA, a region of defined sequence and a base paired stem region.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: October 3, 2000
    Assignee: Gene Shears Pty. Ltd.
    Inventors: James Phillip Haseloff, Wayne Lyle Gerlach, Philip Anthony Jennings, Fiona Helen Cameron
  • Patent number: 6127124
    Abstract: Methods for the determination of nuclease stability of an oligomeric compound and its deletion sequences by capillary gel electrophoresis using laser-induced fluorescence detection (LIF CGE) are provided. Fluorescently labeled oligomeric compounds are treated with one or more agents having nuclease activity resulting in an assay mixture of the original oligomeric compound and its deletion sequences. A diluted aliquot taken directly from the assay mixture is analyzed using LIF CGE. Results of the assay yield quantitative concentrations of the oligomeric compound and each of the deletion sequences. In further embodiments, the invention provides methods for determining the relative binding affinity of one or more oligomeric compounds for a substrate having nuclease activity, and methods for determining the nuclease activity of an enzyme.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: October 3, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Janet M. Leeds, Lendell L. Cummins
  • Patent number: 6127116
    Abstract: The present invention relates to the determination of an authentic HCV genome RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, e.g., for gene therapy of gene vaccines.
    Type: Grant
    Filed: March 4, 1997
    Date of Patent: October 3, 2000
    Assignee: Washington University
    Inventors: Charles M. Rice, Alexander A. Kolykhalov
  • Patent number: 6124133
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of fra-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fra-1. Methods of using these compounds for modulation of fra-1 expression and for treatment of diseases associated with expression of fra-1 are provided.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: September 26, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Jennifer K. Taylor, Lex M. Cowsert
  • Patent number: 6124091
    Abstract: The present invention provides a partial cDNA corresponding to an RNA containing double stranded regions (R-RNA), which, when transcribed in vitro, gives rise to an RNA transcript that activates PKR. An approximately 226-252 bp nucleotide (nt) sequence responsible for activation of PKR (the activation sequence) has been identified within the cDNA and isolated. Antisense oligonucleotides corresponding to specific portions of the 252 nt cDNA fragment stimulate proliferation of different cells in culture. Various portions of the cDNA or R-RNA may also be used to inhibit cell proliferation in cell cultures.The present invention further provides pharmaceutical compositions comprising the subject nucleic acid fragments and oligonucleotides. Kits which comprise at least one of the subject isolated nucleic acid molecules or oligonucleotides and a pharmaceutically acceptable carrier are also provided.
    Type: Grant
    Filed: May 30, 1997
    Date of Patent: September 26, 2000
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Raymond A. Petryshyn